Failure-free survival and radiotherapy in patients with newly diagnosed nonmetastatic prostate cancer: data from patients in the control arm of the STAMPEDE trial.
dc.contributor.author | James, N | |
dc.contributor.author | Spears, M | |
dc.contributor.author | Clarke, Noel W | |
dc.contributor.author | Dearnaley, D | |
dc.contributor.author | Mason, M | |
dc.contributor.author | Parker, C | |
dc.contributor.author | Ritchie, A | |
dc.contributor.author | Russell, J | |
dc.contributor.author | Schiavone, F | |
dc.contributor.author | Attard, G | |
dc.contributor.author | de Bono, J | |
dc.contributor.author | Birtle, A | |
dc.contributor.author | Engeler, D | |
dc.contributor.author | Elliott, T | |
dc.contributor.author | Matheson, D | |
dc.contributor.author | O'Sullivan, J | |
dc.contributor.author | Pudney, D | |
dc.contributor.author | Srihari, N | |
dc.contributor.author | Wallace, J | |
dc.contributor.author | Barber, J | |
dc.contributor.author | Syndikus, I | |
dc.contributor.author | Parmar, M | |
dc.contributor.author | Sydes, M | |
dc.date.accessioned | 2016-01-06T15:25:45Z | en |
dc.date.available | 2016-01-06T15:25:45Z | en |
dc.date.issued | 2015-11-25 | en |
dc.identifier.citation | Failure-free survival and radiotherapy in patients with newly diagnosed nonmetastatic prostate cancer: data from patients in the control arm of the STAMPEDE trial. 2015:1-10 JAMA Oncol | en |
dc.identifier.issn | 2374-2445 | en |
dc.identifier.pmid | 26606329 | en |
dc.identifier.doi | 10.1001/jamaoncol.2015.4350 | en |
dc.identifier.uri | http://hdl.handle.net/10541/592999 | en |
dc.description.abstract | The natural history of patients with newly diagnosed high-risk nonmetastatic (M0) prostate cancer receiving hormone therapy (HT) either alone or with standard-of-care radiotherapy (RT) is not well documented. Furthermore, no clinical trial has assessed the role of RT in patients with node-positive (N+) M0 disease. The STAMPEDE Trial includes such individuals, allowing an exploratory multivariate analysis of the impact of radical RT. | |
dc.language | ENG | en |
dc.rights | Archived with thanks to JAMA oncology | en |
dc.title | Failure-free survival and radiotherapy in patients with newly diagnosed nonmetastatic prostate cancer: data from patients in the control arm of the STAMPEDE trial. | en |
dc.type | Article | en |
dc.contributor.department | Warwick Medical School, University of Warwick, Coventry | en |
dc.identifier.journal | JAMA Oncology | en |
html.description.abstract | The natural history of patients with newly diagnosed high-risk nonmetastatic (M0) prostate cancer receiving hormone therapy (HT) either alone or with standard-of-care radiotherapy (RT) is not well documented. Furthermore, no clinical trial has assessed the role of RT in patients with node-positive (N+) M0 disease. The STAMPEDE Trial includes such individuals, allowing an exploratory multivariate analysis of the impact of radical RT. |